Benzinga · Nov 11, 2026
Cantor Fitzgerald Maintains Overweight on NewAmsterdam Pharma Co, Raises Price Target to $61
Cantor Fitzgerald analyst Steve Seedhouse maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Overweight and raises the price target from $52 to $61.

